Global Information
회사소개 | 문의 | 비교리스트

안드로겐 탈모증 : 파이프라인 리뷰

Androgenic Alopecia - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 257832
페이지 정보 영문 70 Pages
가격
US $ 2,000 ₩ 2,417,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,834,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,251,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


안드로겐 탈모증 : 파이프라인 리뷰 Androgenic Alopecia - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 70 Pages

안드로겐 탈모증은 유전적 질환으로, 경모에서 연모로의 단계적 전환을 특징으로 하고 있습니다. 남녀 모두에서 볼 수 잇는 매우 흔한 질환입니다. 발병 원인은 알레르기, 자극물질, 독소, 화상, 외상, 감염 등입니다.

안드로겐 탈모증(Androgenic Alopecia) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

목차

서론

안드로겐 탈모증 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

개발중인 치료제 : 기업별

파이프라인 제품 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

개발중인 제품 : 기업별

치료제 개발에 참여하고 있는 기업

  • Allergan, Inc.
  • Histogen, Inc.
  • R-Tech Ueno, Ltd.
  • Hygeia Therapeutics, Inc.
  • SWITCH Biotech LLC
  • Polichem S.A.
  • Kasiak Research Pvt. Ltd.

치료제 평가

  • 단독치료(Monotherapy) 제품별
  • 병용치료(Combination Therapy) 제품별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • bimatoprost
  • RK-023
  • Refagro
  • RCH-01
  • Hair Stimulating Complex (HSC)
  • finasteride
  • SM-04554
  • HYG-440
  • (HYG-102 + HYG-440)
  • Small Molecule for Androgenic Alopecia

파이프라인 제품의 최신 동향

휴지 상태인 프로젝트

제품 개발 마일스톤

  • 최신 뉴스와 프레스 릴리스

부록

도표

LSH 14.08.08

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Androgenic Alopecia - Pipeline Review, H2 2016, provides an overview of the Androgenic Alopecia (Dermatology) pipeline landscape.

Androgeneic alopecia is a genetically determined disorder characterized by the gradual conversion of terminal hairs into indeterminate, and finally into vellus, hairs. It is an extremely common disease that affects men and women. Predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Androgenic Alopecia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Androgenic Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Androgenic Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Androgenic Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 8, 4 and 1 respectively.

Androgenic Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Androgenic Alopecia (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Androgenic Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Androgenic Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Androgenic Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Androgenic Alopecia (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Androgenic Alopecia (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Androgenic Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Androgenic Alopecia Overview
  • Therapeutics Development
    • Pipeline Products for Androgenic Alopecia - Overview
  • Androgenic Alopecia - Therapeutics under Development by Companies
  • Androgenic Alopecia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Androgenic Alopecia - Products under Development by Companies
  • Androgenic Alopecia - Companies Involved in Therapeutics Development
    • Aclaris Therapeutics Inc
    • Allergan Plc
    • Almirall SA
    • BiologicsMD Inc
    • Dong-A Socio Holdings Co Ltd
    • Histogen Inc
    • RepliCel Life Sciences Inc
    • RiverTown Therapeutics Inc
    • Samumed LLC
    • Sucampo Pharmaceuticals Inc
    • SWITCH Biotech LLC
  • Androgenic Alopecia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cyclosporine A + minoxidil + RT-175) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimatoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMD-1341 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BRM-421 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-0301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • finasteride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • finasteride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HGEN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCH-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RK-023 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • setipiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-04554 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Androgenic Alopecia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Androgenic Alopecia - Dormant Projects
  • Androgenic Alopecia - Discontinued Products
  • Androgenic Alopecia - Product Development Milestones
    • Featured News & Press Releases
      • Oct 25, 2016: Samumed Successfully Completes a Phase II Androgenetic Alopecia Biopsy Trial Studying Regeneration of Hair Follicles
      • Sep 26, 2016: RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
      • Jul 21, 2016: RepliCel Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
      • Mar 07, 2016: Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia Trial
      • Feb 24, 2016: Cassiopea attains clinical endpoints in Breezula alopecia proof of concept trial
      • Dec 04, 2015: Samumed Announces Increases in Both Hair Count and Hair Density Observed in Its Phase II Study for a Potential Treatment of Androgenetic Alopecia
      • Nov 23, 2015: Samumed Completes Phase II Study for Its Potential Treatment of Androgenetic Alopecia: Safety Data Show No Serious Adverse Events in Any Treated Patient
      • Nov 18, 2015: Samumed to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research
      • Dec 22, 2014: Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
      • Oct 09, 2014: RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum
      • May 20, 2014: RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness
      • Feb 27, 2014: RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine
      • Jan 13, 2014: RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology
      • Dec 19, 2013: RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Androgenic Alopecia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Androgenic Alopecia - Pipeline by Aclaris Therapeutics Inc, H2 2016
  • Androgenic Alopecia - Pipeline by Allergan Plc, H2 2016
  • Androgenic Alopecia - Pipeline by Almirall SA, H2 2016
  • Androgenic Alopecia - Pipeline by BiologicsMD Inc, H2 2016
  • Androgenic Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016
  • Androgenic Alopecia - Pipeline by Histogen Inc, H2 2016
  • Androgenic Alopecia - Pipeline by RepliCel Life Sciences Inc, H2 2016
  • Androgenic Alopecia - Pipeline by RiverTown Therapeutics Inc, H2 2016
  • Androgenic Alopecia - Pipeline by Samumed LLC, H2 2016
  • Androgenic Alopecia - Pipeline by Sucampo Pharmaceuticals Inc, H2 2016
  • Androgenic Alopecia - Pipeline by SWITCH Biotech LLC, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Androgenic Alopecia - Dormant Projects, H2 2016
  • Androgenic Alopecia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Androgenic Alopecia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top
전화 문의
F A Q